As the old saying goes, "If something sounds too good to be true, it probably is."
That clichéd wisdom presents something of a problem for any investor eyeing a new stake in pharmaceutical outfit Pfizer (NYSE: PFE) while its stock is priced at less than 10 times this year's expected per-share profit of $2.98, with a forward-looking dividend yield that's unusually high at just over 6%.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
What's the market seeing? Maybe it's what the market's not seeing. To this end, if you're thinking about diving in, here are the top three things you need to know about Pfizer today.
All stock prices reflect that company's plausible future more so than its past, or even its present. The challenge for investors interested in Pfizer at this time is how far into the future they need to look.
#need
That clichéd wisdom presents something of a problem for any investor eyeing a new stake in pharmaceutical outfit Pfizer (NYSE: PFE) while its stock is priced at less than 10 times this year's expected per-share profit of $2.98, with a forward-looking dividend yield that's unusually high at just over 6%.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
What's the market seeing? Maybe it's what the market's not seeing. To this end, if you're thinking about diving in, here are the top three things you need to know about Pfizer today.
All stock prices reflect that company's plausible future more so than its past, or even its present. The challenge for investors interested in Pfizer at this time is how far into the future they need to look.
#need
9 days ago
